Guggenheim reiterates Buy on Equinix and Abivax with raised targets
Guggenheim kept its Buy rating on Equinix with a $1,235 target and on Abivax with a $175 target, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Guggenheim analysts kept their Buy rating on Equinix and set a price target of $1,235. The target implies a 26.6% gain from the October 19 close of $975.71. The bank points to Equinix's network of 270 properties across 36 countries and more than 10,000 customers as support for steady revenue growth in colocation and interconnection services.
Guggenheim also reaffirmed Buy on Abivax, with a $175 target that implies a 124.5% rise from the October 19 close of $77.95. Analysts say obefazimod has shown strong potential in ulcerative colitis, and many key opinion leaders view it as a best-in-disease option. Abivax plans to submit its NDA by the end of 2026 and expects a launch in 2028.
why it matters
This report covers analyst ratings rather than new company results. For markets, it is a signal on two stocks from different sectors: data centers and biotechnology. The information is reported by TradingView, which cites data from Benzinga.
tags
instruments
sources
- Guggenheim reiterates Buy rating on Equinix, $1235 price target — TradingView, 20 October 2026 at 12:50 UTC
- Guggenheim reiterates Buy rating on Abivax, $175 price target — TradingView, 20 October 2026 at 12:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗